Comparing the current results to its competitors, Entrada Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -53.95 %, faster than the overall decrease of Entrada Therapeutics Inc 's competitors by -12.2 %, recorded in the same quarter.
Entrada Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may develop technologies or therapeutic candidates at a faster pace or with greater effectiveness, potentially impacting the company's business and commercialization activities. In the treatment of Duchenne Muscular Dystrophy (DMD), competitors include PTC Therapeutics, Inc., which markets EMFLAZA (deflazacort); Catalyst Pharmaceuticals, which markets AGAMREE (vamorolone); and ITF Therapeutics, which markets Duvyzat (givinostat).
October 9, 2024
Duchenne muscular dystrophy (DMD) represents one of the most challenging and devastating genetic disorders, characterized by progressive muscle degeneration and weakness. It primarily affects boys and leads to severe functional impairment and reduced lifespan. As the need for effective therapeutic strategies intensifies, Entrada Therapeutics has emerged as a prominent player in this domain, recently showcasing promising results from its expanding Duchenne franchise during the 29th Annual Congress of the World Muscle Society. This article delves into the key findings presented by Entrada Therapeutics regarding its investigational drug, ENTR-601-44, and how these developments may pave the way for novel treatme...
June 24, 2024
Entrada Therapeutics has recently announced the successful completion of preliminary data analysis from their Phase 1 clinical trial ENTR-601-44-101 involving the investigation of ENTR-601-44 in healthy volunteers for the treatment of Duchenne Muscular Dystrophy (DMD). This announcement marks a significant milestone in the quest for innovative treatments for this debilitating genetic disorder, offering hope to the patient community and stakeholders alike. Promising Results from Phase 1 StudyThe ENTR-601-44, designed for patients with Duchenne Muscular Dystrophy, specifically targets the dystrophin gene exon 44. The preliminary data from this study indicate that ENTR-601-44 was well-tolerated among health...
In its ongoing efforts to combat Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics Inc has achieved significant milestones by completing the dosing of the first and second cohorts in its Phase 1 clinical trial for ENTR-601-44-101. This promising development brings new hope to individuals suffering from this devastating rare disease. However, recent financial reports reveal that Entrada s revenue growth in the third quarter of 2023 fell short in comparison to its competitors.
Entrada Therapeutics, a leading biotechnology company focused on innovative therapies, recently announced the successful completion of dosing in the Phase 1 clinical trial for ENTR-601-44, a potential breakthroug...
Audentes Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative gene therapies for serious rare diseases. Their business model revolves around conducting extensive research and development to design and produce these gene therapies. They then collaborate with healthcare providers and regulatory bodies to gain necessary approvals and commercialize their therapies, aiming to provide effective treatments for patients suffering from rare diseases.
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.
Minerva Neurosciences Inc is a biopharmaceutical company that primarily focuses on the development and commercialization of innovative therapies for central nervous system disorders. They aim to identify potential drug candidates, conduct clinical trials, and collaborate with partners to bring novel treatments to market.
Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.
Sources:
Entrada Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Entrada Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
